Chemotherapy Induced Peripheral Neuropathy (CIPN)
There is plenty of evidence that neuropathy of lower limbs negatively impacts a patient’s quality of life. CIPN is experienced by up to 60% of people having taxane or platinum-based chemotherapy, primarily used for breast or colorectal cancer. CIPN is the leading cause of ceasing or reducing cancer treatment. As lower limb experts, podiatrists can have a role in the care of patients with CIPN, however, our understanding on what podiatry involvement should look like and conservative management techniques for this condition is not well understood. This research aims to unpack and begin to fill these knowledge gaps.
Presented by:
Sindhrani Dars completed her Bachelor of Podiatry with Honours from the University of South Australia in 2017. She is currently undertaking her PhD on a population-based investigation of podiatry service use following neurotoxic chemotherapy and podiatry management of Chemotherapy Induced Peripheral Neuropathy (CIPN). Having already published three research articles in tier 1 journals, her research focus is on clinically meaningful outcomes. She is also a tutor and clinical educator at the University of South Australia where she provides supervision and mentoring to undergraduate students. Sindhrani has also worked clinically, with a diverse experience providing a range of services to patients of all age groups.